第四剂mRNA新冠疫苗对奥密克戎变异株在长期护理机构居民中的有效性:加拿大安大略省检测阴性设计研究
结果显示,第四剂相对于第三剂的边际有效性分别为:感染19%、症状性感染31%、重症结局40%;与未接种者相比,第四剂疫苗有效性分别为:感染49%、症状性感染69%、重症结局86%。结论提示在奥密克戎流行期,第四剂可改善长期护理机构居民的保护效果。
要点
- 第四剂相对于第三剂对奥密克戎感染的边际有效性为19%,对症状性感染为31%,对重症结局为40%。
- 与未接种者相比,第四剂对感染、症状性感染和重症结局的有效性分别为49%、69%和86%。
- 疫苗有效性随剂次增加而提高,但第四剂保护持续时间尚不明确。
核心结论
- 与第三剂mRNA新冠疫苗相比,第四剂在奥密克戎优势流行期可改善长期护理机构居民对感染、症状性感染和重症结局的保护。
- 与未接种者相比,第四剂对重症结局有较强保护,但保护持续时间未知。
研究设计与样本
- 检测阴性设计,地点为加拿大安大略省长期护理机构,时间为2021年12月30日至2022年4月27日。
- 采用多因素logistic回归估计边际有效性和疫苗有效性,调整个人特征、合并症、检测周次和既往90天以上阳性检测结果。
主要发现
- 第四剂接种后7天及以上相对于84天及以上前接种第三剂的边际有效性:感染19%(95%CI 12%至26%),症状性感染31%(95%CI 20%至41%),重症结局40%(95%CI 24%至52%)。
- 与未接种者相比,第四剂疫苗有效性:感染49%(95%CI 43%至54%),症状性感染69%(95%CI 61%至76%),重症结局86%(95%CI 81%至90%)。
- 疫苗有效性随每增加一剂次而提高。
关键数值与推荐
- 第四剂接种者中95%接受mRNA-1273作为第四剂。
- 边际有效性比较为第四剂接种后7天及以上 versus 第三剂接种后84天及以上。
- 疫苗有效性比较为接种2、3或4剂 versus 未接种。
临床怎么用
- 在奥密克戎流行期,长期护理机构居民接种第四剂mRNA新冠疫苗可提高对感染、症状性感染和重症结局的保护。
- 第四剂对重症结局的保护较强,但需注意保护持续时间尚不明确。
局限性
- 第四剂保护持续时间未知。
- 研究期间第四剂接种者中95%接受mRNA-1273,可能影响对其他疫苗产品的推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the marginal effectiveness of a fourth versus third dose and the vaccine effectiveness of mRNA covid-19 vaccines BNT162b2 and mRNA-1273 against any infection, symptomatic infection, and severe outcomes (hospital admission or death) related to the omicron variant. DESIGN: Test negative design. SETTING: Long term care facilities in Ontario, Canada, 30 December 2021 to 27 April 2022. PARTICIPANTS: After exclusions, 61 344 residents aged 60 years or older across 626 long term care facilities in Ontario, Canada who were tested for SARS-CoV-2 were included. MAIN OUTCOME MEASURES: Laboratory confirmed omicron SARS-CoV-2 infection (any and symptomatic) by reverse transcription polymerase chain reaction (RT-PCR), and hospital admission or death. Multivariable logistic regression was used to estimate marginal effectiveness (four versus three doses) and vaccine effectiveness (two, three, or four doses versus no doses) while adjusting for personal characteristics, comorbidities, week of test, and previous positive SARS-CoV-2 test result more than 90 days previously. RESULTS: 13 654 residents who tested positive for omicron SARS-CoV-2 infection and 205 862 test negative controls were included. The marginal effectiveness of a fourth dose (95% of vaccine recipients received mRNA-1273 as the fourth dose) seven days or more after vaccination versus a third dose received 84 or more days previously was 19% (95% confidence interval 12% to 26%) against infection, 31% (20% to 41%) against symptomatic infection, and 40% (24% to 52%) against severe outcomes. Vaccine effectiveness in vaccine recipients (compared with unvaccinated) increased with each additional dose, and for a fourth dose was 49% (95% confidence interval 43% to 54%) against infection, 69% (61% to 76%) against symptomatic infection, and 86% (81% to 90%) against severe outcomes. CONCLUSIONS: The findings suggest that compared with a third dose of mRNA covid-19 vaccine, a fourth dose improved protection against infection, symptomatic infection, and severe outcomes among long term care residents during an omicron dominant period. A fourth vaccine dose was associated with strong protection against severe outcomes in vaccinated residents compared with unvaccinated residents, although the duration of protection remains unknown.
引用
- Grewal R, Kitchen SA, Nguyen L, et al. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study. BMJ. 2022. PMID: 35793826. doi:10.1136/bmj-2022-071502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。